Fig. 1

Curcumin enhances anticancer effect of gefitinib on NSCLC cell and suppresses EGFR activity. a H157, H1299 and PC9 cell lines were growth in complete media in the presence of 5 μM gefitinib (top), or 5 μM curcumin (nether) for 24, 48, 72, 96 h. Fold increase in cell counts normalized to zero hour counts of respective cell lines are represent (***P<0.001). b The three cell lines were grown in the presence DMSO or 10 μM gefitinib in complete media. BrdU substrate was added 48 h after drug treatment and assayed after 24 h. H157 c, H1299 d and PC9 e cells were treated with gefitinib, or curcumin alone, or the two combination at indicated concentrations for 48 h. Cell viability was measured by CCK-8 assay (*P<0.05; ***P<0.001). f H157, H1299 and PC9 cell lines were pre-treated with curcumin or gefitinib alone, or the two combination at indicated concentrations for 12 h, and then EGF (30 ng/mL) was added for 1 h. Immunoblot analysis was used to determine p-EGFR and total EGFR expression. Actin was used as aloading control in immunoblots. Similar results were obtained from three independent experiments. Typical immunoblots were presented in the Figure